Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcumin, the principal active component of turmeric, has been investigated for its potential to support cancer patients undergoing chemotherapy, primarily by reducing side effects such as inflammation, mucositis, neurotoxicity, and fatigue. Several preclinical studies and a growing number of small clinical trials suggest that curcumin exhibits anti-inflammatory, antioxidant, and cytoprotective properties, which may help mitigate some of the toxicities associated with chemotherapy. For example, curcumin has been shown to modulate molecular pathways that are implicated in inflammation (such as NF-κB and COX-2), and animal studies indicate it can reduce chemotherapy-induced organ damage.

A few randomized controlled trials in humans have explored curcumin supplementation during chemotherapy. Some of these studies report modest benefits, such as reduced severity of oral mucositis in patients with head and neck cancers, or lessened peripheral neuropathy in patients receiving paclitaxel. However, sample sizes are typically small, and results are sometimes inconsistent or not statistically significant.

Overall, current evidence for curcumin’s effectiveness in reducing chemotherapy side effects is preliminary and limited by methodological weaknesses. There are also concerns about the bioavailability of oral curcumin. Larger, well-designed clinical trials are needed to establish clear benefits and safety. Despite these limitations, the use of curcumin is scientifically motivated, and it continues to be the subject of active research for supportive care in oncology.

More about curcumin
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by curcumin

Products containing curcumin

Nature's Sunshine Turmeric Curcumin (Formerly CurcuminBP)